0001213900-22-002152.txt : 20220114 0001213900-22-002152.hdr.sgml : 20220114 20220114162856 ACCESSION NUMBER: 0001213900-22-002152 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220110 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Change in Shell Company Status ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220114 DATE AS OF CHANGE: 20220114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REVELATION BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001810560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 843898466 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39603 FILM NUMBER: 22532166 BUSINESS ADDRESS: STREET 1: 4660 LAJOLLA VILLAGE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 650-800-3717 MAIL ADDRESS: STREET 1: 4660 LAJOLLA VILLAGE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Petra Acquisition Inc. DATE OF NAME CHANGE: 20200423 8-K 1 ea154019-8k_revelation.htm CURRENT REPORT
0001810560 false --12-31 0001810560 2022-01-10 2022-01-10 0001810560 REVB:UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember 2022-01-10 2022-01-10 0001810560 REVB:CommonStockParValue0.001PerShareMember 2022-01-10 2022-01-10 0001810560 REVB:RedeemableWarrantsEachExercisableForShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2022-01-10 2022-01-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 14, 2022 (January 10, 2022)

 

REVELATION BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-39603   84-3898466
(State or Other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122

(Address of Principal Executive Offices) (Zip Code)

 

(650) 800-3717

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one share of common stock and one-half of one redeemable warrant   REVBU   The Nasdaq Stock Market LLC
Common stock, par value $0.001 per share   REVB   The Nasdaq Stock Market LLC
Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share   REVBW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

Introductory Note

 

On January 10, 2022 (the “Closing Date”), Petra Acquisition, Inc., a Delaware corporation and our predecessor company (“Petra”), consummated the previously announced business combination (the “Business Combination”), pursuant to the terms of the agreement and plan of merger, dated as of August 29, 2021 (the “Business Combination Agreement”), by and among Petra, Petra Acquisition Merger, Inc., a Delaware corporation and wholly-owned subsidiary of Petra (“Merger Sub”), and Revelation Biosciences, Inc. (“Old Revelation”). Pursuant to the Business Combination Agreement, on the Closing Date, (i) Merger Sub merged with and into Old Revelation (the “Merger”), with Old Revelation as the surviving company in the Merger, and, after giving effect to such Merger, Old Revelation was renamed Revelation Biosciences Sub, Inc. and became a wholly-owned subsidiary of Petra and (ii) Petra changed its name to “Revelation Biosciences, Inc.” (“New Revelation” or the “Company” f/k/a Petra Acquisition, Inc.).

 

In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the effective time of the Merger (the “Effective Time”), (i) each share of common stock and preferred stock of Old Revelation outstanding as of immediately prior to the Effective Time was exchanged for shares of common stock, par value $0.001 per share, of New Revelation (“Common Stock”) based on the agreed upon conversion rate of 2.725 (the “Common Stock Exchange Ratio); (ii) each Old Revelation RSU Award (as defined in the Business Combination Agreement) outstanding as of immediately prior to the Effective Time was assumed by New Revelation and was converted into that number of whole New Revelation Rollover RSU Awards (as defined in the Business Combination Agreement) based on the Common Stock Exchange Ratio; and (iii) each Old Revelation Warrant (as defined in the Business Combination Agreement) outstanding as of immediately prior to the Effective Time was assumed by New Revelation and was converted into that number of whole New Revelation Rollover Warrants (as defined in the Business Combination Agreement) based on the Common Stock Exchange Ratio, at an exercise price per share of Common Stock equal to (x) the exercise price per share of Old Revelation common stock of such Old Revelation Warrant divided by (y) the Common Stock Exchange Ratio.

 

No fraction of a share of Common Stock was issued at the Closing, and each person who was otherwise entitled to a fraction of a share of Common Stock (after aggregating all fractional shares of Common Stock that otherwise would be received by such holder) received the number of shares of Common Stock rounded in the aggregate to the nearest whole share of Common Stock.

 

Unless the context otherwise requires, “New Revelation,” “we,” “us,” “our,” and the “Company” refer to Revelation Biosciences, Inc., a Delaware corporation. All references herein to the “Board” refer to the board of directors of the Company (the “Board”). All references herein to the “Closing” refer to the closing of the transactions contemplated by the Business Combination Agreement, including the Merger and the Business Combination (collectively, the “Transactions”). 

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

The disclosure set forth in the “Introductory Note” above is incorporated by reference into this Item 2.01.

 

As previously disclosed on a Current Report on Form 8-K filed on January 12, 2022, Petra held a special meeting of stockholders on January 6, 2022 (the “Special Meeting”) at which the stockholders of Petra considered and approved, among other matters, a proposal to adopt the Business Combination Agreement and the transactions contemplated therein. On the Closing Date, the parties to the Business Combination Agreement consummated the Transactions.

 

1

 

At the Closing, of the 10,500,000 shares of Common Stock constituting the Merger Consideration, (i) an aggregate of 9,871,343 shares of Common Stock were issued in exchange for the Old Revelation stock outstanding as of immediately prior to the Effective Time, (ii) 167,867 shares of Common Stock were reserved for issuance for Revelation Rollover Warrants outstanding as of immediately prior to the Effective Time and (iii) 460,706 shares of Common Stock were reserved for issuance for Revelation Rollover RSU’s outstanding as of immediately prior to the Effective Time.

 

Immediately after giving effect to the Business Combination, there were 12,944,213 shares of Common Stock outstanding, and 1,294,421 shares of Common Stock reserved for future issuance under the Equity Incentive Plan.

 

In connection with the Merger, holders of 3,480,362 shares of Petra common stock exercised their right to redeem such shares for cash at a price of approximately $10.20 per share for payments in the aggregate of approximately $35.5 million. On the Closing Date, approximately $7.6 million was escrowed pursuant to that certain Forward Share Purchase Agreement entered into by and between Petra and Meteora Special Opportunity Fund I, LP, a Delaware limited partnership, and Meteora Capital Partners, LP, a Delaware limited partnership (collectively, “Meteora”) and approximately $4.2 million was released to the Company.

 

The material terms and conditions of the Business Combination Agreement and its December 16, 2021 proxy statement/prospectus (the “Proxy Statement/Prospectus”) included in Petra’s Registration Statement on Form S-4 (File No. 333-259638), originally filed with the Securities and Exchange Commission (“SEC”) on September 20, 2021, under the headings titled “Proposal No. 1 – The Business Combination Proposal” beginning on page 102 thereto, and that information is incorporated herein by reference. The foregoing description of the Forward Share Purchase Agreement does not purport to be complete and is qualified in its entirety by the text of the Forward Share Purchase Agreement, which was filed as Exhibit 10.2 to a Current Report on Form 8-K filed with the SEC on December 23, 2021.

 

FORM 10 INFORMATION

 

Prior to the Closing, the Company was a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) with no operations, and was formed as a vehicle to effect a business combination with one or more operating businesses.

 

Item 2.01(f) of Form 8-K states that if the predecessor registrant was a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act), as Petra was immediately before the Business Combination, then the registrant must disclose the information that would be required if the registrant were filing a general form for registration of securities on Form 10. Accordingly, the Company, as the successor registrant to Petra following the consummation of the Business Combination, is providing the information below that would be included in a Form 10 if the Company were to file a Form 10. Please note that the information provided below relates to the Company as the combined company after the consummation of the Transactions unless otherwise specifically indicated or the context otherwise requires.

 

Cautionary Note Regarding Forward-Looking Statements

 

The Company makes forward-looking statements in this Current Report on Form 8-K and in documents incorporated herein by reference. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. These forward-looking statements include statements about future financial and operating results of the Company; benefits of the Business Combination; statements about the plans, strategies and objectives of management for future operations of the Company; statements regarding future performance; and other statements regarding the Business Combination. In some cases, you can identify these forward-looking statements by the use of terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative version of these words or other comparable words or phrases, but the absence of these words does not mean that a statement is not forward-looking.

 

2

 

These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the Proxy Statement/Prospectus. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them and to the risk factors.

 

Forward-looking statements are based on information available at the date such statements were made. The forward-looking statements in this Current Report on Form 8-K and in any document incorporated herein by reference should not be relied upon as representing the Company’s views as of any subsequent date, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. There can be no assurance that future developments affecting us will be those that we have anticipated. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

Please see the other risks and uncertainties set forth in the Proxy Statement/Prospectus in the section titled “Risk Factors” beginning on page 38 of the Proxy Statement/Prospectus and incorporated herein by reference.

 

Business

 

The business of Petra prior to the Business Combination is described in the Proxy Statement/Prospectus under the heading “Information About Petra” beginning on page 139 thereto and that information is incorporated herein by reference. The business of New Revelation after the Business Combination is described in the Proxy Statement/Prospectus beginning on page 155 under the heading “Information About Revelation” and that information is incorporated herein by reference.

 

Properties

 

Our principal executive offices are located at 4660 La Jolla Village Dr., Suite 100, San Diego, CA 92122, which are leased on a short-term basis. We also lease 2,140 square feet of laboratory space at 11011 Torreyana Road, Suite 102, San Diego, CA 92121.

 

Risk Factors

 

The risks associated with New Revelation’s business are described in the Proxy Statement/Prospectus under the headings “Risk Factors” and “Risks Related to Ownership of New Revelation Following the Business Combination” beginning on pages 38 and 72, respectively, and that information is incorporated herein by reference.

 

Financial Information

 

Reference is made to the disclosure set forth in Item 9.01 of this Current Report on Form 8-K concerning the financial information of the Company. Reference is further made to the disclosures contained in the Proxy Statement/Prospectus under the headings “Index to Financial Statements,” “Petra Acquisition, Inc. Audited Financial Statements,” “Petra Acquisition, Inc. Unaudited Financial Statements,” “Revelation Biosciences, Inc. Audited Financial Statements,” “Revelation Biosciences, Inc. Unaudited Financial Statements,” “Selected Historical Financial Information of Revelation,” “Selected Historical Financial Information of Petra,” “Selected Unaudited Pro Forma Condensed Combined Financial Information,” “Comparative Historical and Unaudited Pro Forma Combined per Share Financial Information,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Revelation,” and “Management’s Discussion and Analysis of Results of Financial Condition and Results of Operations of Petra” beginning on pages F-1, F-2, F-21, F-37, F-52, 31, 32, 93, 36, 207 and 151, respectively, each of which is incorporated herein by reference.

 

3

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth information regarding the beneficial ownership of our Common Stock as of the Closing Date, after giving effect to the Closing of the Transactions, by:

 

  each person known to be the beneficial owner of more than 5% of our outstanding Common Stock;
     
  each of our executive officers and directors; and
     
  all of our executive officers and directors as a group following the consummation of the Transactions.

 

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the vesting and issuance of RSU’s, within 60 days. Shares subject to RSU’s that are currently vested, vesting or issuable within 60 days of the Closing Date are considered outstanding and beneficially owned by the person holding such options for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, New Revelation believes that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. Unless otherwise noted, the business address of each of the directors and executive officers of New Revelation is 4660 La Jolla Village Dr., Suite 100, San Diego, CA 92122.

 

The percentage of beneficial ownership of New Revelation is calculated based on 12,944,213 shares of Common Stock outstanding immediately after giving effect to the Transactions and do not take into account (i) the issuance of shares upon exercise of warrants to purchase 10,679,464 shares of Common Stock currently outstanding and (ii) the issuance of 460,706 shares of Common Stock for outstanding Rollover RSU’s.

 

   Common Stock 
Name and Address of Beneficial Owner  Share
Beneficially
Owned
   % of
Outstanding
Shares of
Common Stock
 
Directors and Executive Officers(1):           
James Rolke(2)   702,389    5.4%
George Tidmarsh, M.D., Ph.D(3)   1,921,375    14.8%
Jennifer Carver, BSN, MBA(4)   110,974    * 
Jess Roper(5)   42,844    * 
Curt LaBelle, MD(6)   21,422    * 
Chester S. Zygmont, III(7)   689,488    5.3%
All Directors and Executive Officers as a group (Six individuals)   3,488,492    26.6%
Five Percent Holders:          
AXA IM Prime Impact Fund(8)   1,958,984    15.1%
Petra Investment Holdings, LLC(9)   1,769,538    13.7%
LifeSci Venture Partners II, LP & Affiliates(10)   1,043,749    8.1%
Monashee Solitario Fund LP (11)   915,569    7.1%

 

 

*Less than one percent.

(1)Unless otherwise indicated, the business address of each of the individuals is c/o Revelation Biosciences, Inc., 4660 La Jolla Village Dr., Suite 100, San Diego, CA 92122.
(2)Consists of (i) 681,302 shares of Common Stock held directly by Mr. Rolke, (ii) 2,144 shares of Common Stock held by Mr. Rolke’s spouse, and (iii) 18,943 shares of Common Stock from Rollover RSU’s vesting and issuable within 60 days to Mr. Rolke.
(3)Consists of (i) 1,473,335 shares of Common Stock held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust, (ii) 405,196 shares of Common Stock held directly by Dr. Tidmarsh, and (iii) 42,844 shares of Common stock from Rollover RSU’s vesting and issuable within 60 days to Dr. Tidmarsh.
(4)Consists of (i) 68,130 shares of Common Stock held directly by Ms. Carver and (ii) 42,844 shares of Common stock from Rollover RSU’s vesting and issuable within 60 days to Ms. Carver.
(5)Consists of 42,844 shares of Common stock from Rollover RSU’s vesting and issuable within 60 days to Mr. Roper.
(6)Consists of 21,422 shares of Common stock from Rollover RSU’s vesting and issuable within 60 days to Dr. LaBelle.
(7)Consists of (i) 463,285 shares of Common Stock held by The Zygmont Family Trust Dated October 25, 2016, (ii) 218,017 shares of Common Stock held by Czeslaw Capital Fund, LLC, (iii) 2,144 shares held by Mr. Zygmont’s spouse, and (iv) 6,042 shares of Common stock from Rollover RSU’s vesting and issuable within 60 days to Mr. Zygmont.
(8)AXA IM Prime Impact Master Fund ISCA SICAV-RAIF is managed by AXA Investment Managers UK Limited located at 22 Bishopsgate, London EC2N 4BQ, United Kingdom. AXA IM PRIME IMPACT GP S.à r.l., 2-4, rue Eugène Ruppert, L-2453 Luxembourg, is the general partner of the fund. Messrs. Paul Guillaume, Mirko Dietz, Arnold Spruit are the directors of both entities and collectively make voting and investment decisions with respect to the shares owned.
(9)Represents securities held by Petra Investment Holdings, LLC, our sponsor, of which Mr. Typaldos and Mr. Fitzpatrick are each a member, with Mr. Typaldos owning 80% and Mr. Fitzpatrick owning 20%.
(10)Consists of 412,722 shares held by Andrew McDonald, 256,021 shares held by Paul Yook, 214,245 shares held by LifeSci Venture Partners II, LP, 136,260 shares held by Yehuda Rice.
(11)Monashee Investment Management LLC is the investment advisor Monashee Solitario Fund LP. Jeff Muller may be deemed to have shared voting and investment power of the shares held by the Monashee Solitario Fund LP. The address for Monashee Investment Management LLC is 75 Park Plaza, 2nd Floor, Boston, MA 02116.

  

4

 

Directors and Executive Officers

 

Effective as of the Effective Time, in connection with the Business Combination, the size of the Board was set at five members. George F. Tidmarsh MD, PhD, James Rolke, Jennifer Carver, Jess Roper and Curt LaBelle MD, were appointed to serve as directors on the Board. Dr. LaBelle and Ms. Carver were appointed to serve as the Class A directors, with terms expiring at the Company’s 2022 annual meeting. Messrs. Rolke and Roper were appointed to serve as the Class B directors, with terms expiring at the Company’s 2023 annual meeting, and Dr. Tidmarsh was appointed to serve as the Class C director, with a term expiring at the Company’s 2024 annual meeting.

 

New Revelation’s directors and officers after the consummation of the Transactions are described in the Proxy Statement/Prospectus under the heading “Management of New Revelation Biosciences After the Business Combination” beginning on page 203 and is incorporated herein by reference.

 

Committees of the Board of Directors

 

Effective as of the Effective Time, the Board appointed Mr. Roper, Dr. Tidmarsh and Ms. Carver to serve as members of the Audit Committee, with Mr. Roper to serve as the Chairman of the Audit Committee. Effective as of the Effective Time, the Board appointed Drs. Tidmarsh and LaBelle and Mr. Roper to serve as members of the Compensation Committee, with Dr. LaBelle to serve as the Chairman of the Compensation Committee. Effective as of the Effective Time, the Board appointed Ms. Carver, and Drs. Tidmarsh and LaBelle to serve as members of the Nominating and Governance Committee, with Ms. Carver to serve as the Chairman of the Nominating and Governance Committee.

 

Executive Compensation

 

Information about the executive compensation of New Revelation’s executive officers is contained in the Proxy Statement/Prospectus beginning on page 200 under the heading “Executive Officer and Director Compensation of Revelation” is incorporated herein by reference.

 

Certain Relationships and Related Transactions, and Director Independence

 

Certain Relationships and Related Transactions

 

Certain relationships and related party transactions of the Company are described in the Proxy Statement/Prospectus beginning on page 243 under the heading “Certain Relationships and Related Person Transactions” and that information is incorporated herein by reference.

  

Director Independence

 

The Board has determined that each of the directors of the Company other than Mr. Rolke, qualify as independent directors, as defined under the listing rules of The Nasdaq Stock Market LLC (the “Nasdaq listing rules”), and that the Board consists of a majority of “independent directors,” as defined under the rules of the SEC and Nasdaq listing rules relating to director independence requirements.

 

Legal Proceedings

 

None.

 

Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters

 

Market Information and Holders

 

Petra’s units, common stock and public warrants were historically listed on the Nasdaq Capital Market under the symbols “PAICU,” “PAIC,” and “PAICW,” respectively. On January 11, 2022, the Company’s Units, Common Stock and Warrants began trading on the Nasdaq Capital Market under the new trading symbols REVBU, REVB and REVBW, respectively.

 

As of the Closing Date and following the Closing of the Transactions, the Company had 21,136 units issued and outstanding held of record by one holder, 12,923,077 shares of Common Stock issued and outstanding held of record by 154 holders, and 10,490,461 warrants outstanding held of record by two holders.

 

Dividends

 

The Company has not paid any cash dividends on shares of Petra common stock to date. The Company does not anticipate paying any cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the sole discretion of the Board and will depend on, among other things, the Company’s results of operations, cash requirements, financial condition, contractual restrictions and other factors that the Board may deem relevant.

 

5

 

Description of Registrant’s Securities to be Registered

 

The disclosure contained in the Proxy Statement/Prospectus beginning on page 221 under the heading “Description of New Revelation’s Securities After the Business Combination” is incorporated herein by reference.

 

Financial Statements and Supplementary Data

 

The information set forth under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

Not applicable.

  

Item 5.01 Change in Control of Registrant.

 

The information set forth in the section entitled “Introductory Note” and in the section entitled “Security Ownership of Certain Beneficial Owners and Management” in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference. 

 

As a result of the Closing of the Transactions, including the completion of the Business Combination pursuant to the Business Combination Agreement, a change of control of Petra has occurred, and the stockholders of Petra as of immediately prior to the Closing held 23.7% of our Common Stock immediately following the Closing.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective upon the Closing, each of Andreas Typaldos, David Dobkin, Anthony Hayes, Robert Nicholson, Barry Dennis and William Carson ceased serving as a director of Petra and Andreas Typaldos and Sean Fitzpatrick ceased serving as executive officers of Petra.

 

The information contained in the Proxy Statement/Prospectus beginning on page 203 under the heading “Management of New Revelation After the Business Combination,” including the biographical information concerning such executive officers and directors, and the information contained under the heading “Certain Relationships and Related Transactions” in Item 2.01 of this Current Report on Form 8-K are incorporated herein by reference.

 

New Revelation 2021 Equity Incentive Plan

 

At the Special Meeting, the Petra stockholders considered and approved the Revelation Biosciences, Inc. 2021 Equity Incentive Plan (the “Equity Incentive Plan”). A summary of the Equity Incentive Plan is contained in the Proxy Statement/Prospectus beginning on page 130 under the heading “Proposal No. 6 – The Equity Incentive Plan Proposal.” That summary of the Equity Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the text of the Equity Incentive Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

6

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

At the Special Meeting, Petra’s stockholders voted and approved, among other things, the Charter Amendment Proposal, which is described in greater detail in the Proxy Statement/Prospectus in the section titled “Proposal No. 3 – The Charter Amendment Proposal” beginning on page 125 and “Proposal 4- The Advisory Charter Proposals” beginning on page 126. In connection with the consummation of the Transactions, Petra changed its name to “Revelation Biosciences, Inc.” and adopted the third amended and restated certificate of incorporation (the “Restated Charter”), which became effective upon filing with the Secretary of State of the State of Delaware on January 10, 2022.

 

The description of the Restated Charter and the general effect of the Restated Charter upon the rights of the holders of Common Stock is included in the Proxy Statement/Prospectus in the sections titled “Proposal No. 3 – The Charter Amendment Proposal” beginning on page 125, “Proposal 4- The Advisory Charter Proposals” beginning on page 126, “Description of New Revelation’s Securities After the Business Combination” beginning on page 221, and “Comparison of Corporate Governance and Stockholder Rights,” beginning on page 231, which are incorporated herein by reference.

 

Upon the Closing of the Transactions, New Revelation adopted amended and restated bylaws (the “Restated Bylaws”) to be consistent with the Restated Charter and to make certain other changes that the Board deemed appropriate for a public operating company.

 

The summaries described herein are qualified in their entirety by reference to the text of the Restated Charter and the Restated Bylaws, which are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

 

Item 5.06 Changes in Shell Company Status.

 

As a result of the Business Combination, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing. A description of the Business Combination and the terms of the Merger Agreement are included in the Proxy Statement/Prospectus in the section entitled “Proposal No. 1—The Business Combination Proposal” beginning on page 102, which is incorporated herein by reference. Further reference is made to the information contained in Item 2.01 of this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(a) Financial statements of business acquired.

 

The audited financial statements of Old Revelation as of December 31, 2020, the related statement of operations, changes in stockholders’ equity, and cash flows, for the period from May 4, 2020 (inception) to December 31, 2020 are included in the Proxy Statement/Prospectus beginning on page F-37 and are incorporated herein by reference.

 

The unaudited condensed financial statements of Old Revelation as of September 30, 2021 and for the nine months ended September 30, 2021 for the period from May 4, 2020 (inception) to September 30, 2020 are included in the Proxy Statement/Prospectus beginning on page F-52 and are incorporated herein by reference.

 

The audited condensed consolidated financial statements of Petra as of December 31, 2020 and 2019, and the related statements of operations, stockholders’ deficit, and cash flows, for the year ended December 31, 2020 and the period from November 20, 2019 (inception) to December 31, 2019 are included in the Proxy Statement/Prospectus beginning on page F-2 and are incorporated herein by reference.

 

The unaudited condensed consolidated financial statements of Petra as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020 are included in the Proxy Statement/Prospectus beginning on page F-21 and are incorporated herein by reference.

 

7

 

(b) Pro forma financial information.

 

The unaudited pro forma combined condensed consolidated balance sheet of the Company as of September 30, 2021 and the unaudited pro forma combined condensed consolidated statement of operations for the nine months ended September 30, 2021 and for the year ended December 31, 2020 of the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

(c) None.

 

(d) Exhibits.

 

Exhibit 
Number
  Description
2.1+   Agreement and Plan of Merger (incorporated by reference to Exhibit 2.1 to Petra Acquisition, Inc.’s Registration Statement on Form S-4 (File No. 333-259638 ) filed with the SEC on December 13, 2021)
3.1   Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to Petra Acquisition, Inc.’s Registration Statement on Form S-4 (File No. 333-259638 ) filed with the SEC on December 13, 2021)
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to Petra Acquisition, Inc.’s Registration Statement on Form S-4 (File No. 333-259638 ) filed with the SEC on December 13, 2021)
4.1   Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to Petra Acquisition, Inc.’s Registration Statement on Form S-4 (File No. 333-259638 ) filed with the SEC on December 13, 2021)
4.2   Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.4 to Petra Acquisition, Inc.’s Registration Statement on Form S-4 (File No. 333-259638 ) filed with the SEC on December 13, 2021)
4.3   Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to Petra Acquisition, Inc.’s Registration Statement on Form S-4 (File No. 333-259638 ) filed with the SEC on December 13, 2021)
10.1   Revelation Biosciences, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to Petra Acquisition, Inc.’s Registration Statement on Form S-4 (File No. 333-259638 ) filed with the SEC on December 13, 2021)
21.1*   List of Subsidiaries.
99.1*   Unaudited pro forma condensed combined financial information of the Company as of and for the nine months ended September 30, 2021 and for the year ended December 31, 2020
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

+Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.
*Filed herewith.

 

8

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 14, 2022

 

  REVELATION BIOSCIENCES, INC.
     
  By: /s/ Chester S. Zygmont, III
  Name:   Chester S. Zygmont, III
  Title: Chief Financial Officer

 

 

9

 

 

EX-21.1 2 ea154019ex21-1_revelation.htm LIST OF SUBSIDIARIES.

Exhibit 21.1

 

List of Subsidiaries

  

Name   Jurisdiction of Incorporation   Doing Business As
Revelation Biosciences Sub, Inc.   Delaware   Revelation Biosciences

 

 

 

EX-99.1 3 ea154019ex99-1_revelation.htm UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF THE COMPANY AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND FOR THE YEAR ENDED DECEMBER 31, 2020

Exhibit 99.1

 

UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION

 

Capitalized terms used but not defined in this Exhibit 99.1 shall have the meanings ascribed to them in the Current Report on Form 8-K (the “Form 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on January 14, 2022 and, if not defined in the Form 8-K, included in the Company’s effective proxy statement/prospectus dated December 16, 2021 (the “Proxy Statement”), on file with the SEC and incorporated by reference. Any references to the Proxy Statement within the Unaudited Pro Forma Condensed Combined Financial Information refers to the proxy statement on file with the SEC dated December 16, 2021, and incorporated herein by reference.

 

Basis of Presentation and Background

 

The following unaudited pro forma combined condensed consolidated financial statements are based on the separate historical financial statements of Old Revelation and Petra and give effect to the merger, including pro forma assumptions and adjustments related to the merger, as described in the accompanying notes to the unaudited pro forma combined condensed consolidated financial statements. The unaudited pro forma combined condensed consolidated balance sheet as of September 30, 2021, is presented as if the merger had occurred on September 30, 2021. The unaudited pro forma combined condensed consolidated statement of operations for the nine-months ended September 30, 2021, and the year ended December 31, 2020, gives effect to the merger, as if it had been completed on January 1, 2020. The historical financial information has been adjusted on a pro forma basis to reflect factually supportable items that are directly attributable to the merger and, with respect to the statement of operations only, expected to have a continuing impact on consolidated results of operations.

 

The unaudited pro forma combined condensed consolidated statement of operations does not include the effects of the costs associated with any integration or restructuring activities resulting from the merger, as they are nonrecurring in nature. However, the unaudited pro forma combined condensed consolidated balance sheet includes a pro forma adjustment to reduce cash and shareholders’ equity to reflect the payment of certain anticipated merger costs.

 

The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Petra and Old Revelation, adjusted to give effect to the Merger and other events contemplated by the Business Combination Agreement. The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X as amended by the final rule, Release 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses.”

 

The unaudited pro forma condensed combined balance sheet as of September 30, 2021, combines the adjusted balance sheet of Petra with the historical condensed consolidated balance sheet of Old Revelation on a pro forma basis as if the Merger and the other events contemplated by the Business Combination Agreement, summarized below, had been consummated on September 30, 2021.

 

The unaudited pro forma condensed combined statement of operations for the nine-months ended September 30, 2021, combines the historical unaudited statement of operations of Petra with the historical unaudited condensed statement of operations of Old Revelation for the nine-months ended September 30, 2021, and the twelve-months ended December 31, 2020 combines the historical audited statement of operations of Old Revelation for the period from May 4, 2020 (inception) through December 31, 2020 with the historical audited statement of operations of Petra for the twelve months ended December 31, 2020, giving effect to the transaction as if the Merger and other events contemplated by the Business Combination Agreement had been consummated on January 1, 2020.

 

The unaudited pro forma condensed combined financial information was derived from and should be read in conjunction with the following historical financial statements and the accompanying notes:

 

the historical unaudited financial statements of Petra as of and for the nine-months ended September 30, 2021, incorporated by reference in this form 8-K,

 

the historical audited financial statements of Petra as of December 31, 2020, incorporated by reference in this form 8-K,

 

1

 

 

the historical unaudited condensed financial statements of Old Revelation as of and for the nine-months ended September 30, 2021, incorporated by reference in this form 8-K,

 

the historical audited financial statements of Old Revelation for the period from May 4, 2020 (Inception) though December 31, 2020, incorporated by reference in this form 8-K, and

 

other information relating to Petra and Old Revelation, including the Business Combination Agreement and the description of certain terms set forth thereof and the financial and operational condition of Petra and Old Revelation (see “Proposal No. 1 — The Business Combination Agreement,” “Petra’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Revelation Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in the Proxy Statement/Prospectus is included in this Form 8-K or incorporated by reference.

 

Management has made significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented.

 

The pro forma adjustments reflecting the consummation of the Business Combination are based on certain currently available information and certain assumptions and methodologies that Petra believes are reasonable under the circumstances. The unaudited condensed combined pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments, and it is possible the difference may be material. Petra believes that its assumptions and methodologies provide a reasonable basis for presenting all the significant effects of the Business Combination based on information available to management at this time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information.

 

The unaudited pro forma condensed combined financial information is not necessarily indicative of what the actual results of operations and financial position would have been had the Business Combination taken place on the dates indicated, nor are they indicative of the future consolidated results of operations or financial position of the Combined Company. The unaudited pro forma condensed combined financial information should be read in conjunction with the historical financial statements and notes thereto of Petra and Revelation.

 

On January 10, 2022, Petra and Old Revelation, consummated the previously announced Business Combination, pursuant to the terms of the agreement and plan of merger, dated as of August 29, 2021, by and among Petra, Merger Sub, and Old Revelation. Pursuant to the Business Combination Agreement, on the Closing Date, (i) Merger Sub merged with and into Old Revelation, with Old Revelation as the surviving company in the Merger, and, after giving effect to such Merger, Old Revelation was renamed Revelation Biosciences Sub, Inc. and became a wholly-owned subsidiary of Petra and (ii) Petra changed its name to “Revelation Biosciences, Inc..” The Business Combination was accounted for as a reverse merger in which Old Revelation issued stock for the net assets of Petra, accompanied by a recapitalization. The net assets of Petra are stated at historical cost, with no goodwill or other intangible assets recorded upon closing. Historical operations will be those of Old Revelation.

 

The aggregate consideration paid to Old Revelation upon the closing of the Merger was 9,871,343 shares of New Revelation common stock. The unaudited pro forma condensed combined financial information contained herein incorporates the results of Petra’s shareholders having elected to redeem 2,544,127 and 3,480,692 shares of their Common Stock for $25,695,682 and $35,510,020 in cash based upon actual redemptions on October 8, 2021 and January 6, 2022, respectively.

 

2

 

 

Revelation Biosciences, Inc. and Petra Acquisition Inc.
Unaudited Pro Forma Condensed Combined Balance Sheet
(In thousands), except per share amounts
As of September 30, 2021

 

   As of
September 30,
2021
   Transaction      As of
September 30,
2021
 
   Revelation
(Historical)
   Petra
(Historical)
   Accounting
Adjustments
      Pro Forma
Combined
 
ASSETS                   
Current assets:                   
Cash and cash equivalents  $4,137   $   $5,163   A  $8,402 
              (918)  B     
              20   C     
Marketable securities       20    (20)   C    
Prepaid expenses and other current assets   1,565    19           1,584 
Total current assets   5,702    39    4,245       9,986 
Non-current assets:                       
Marketable securities held in Trust Account       73,516    (65,891)  A   7,625 
Equipment, net   138               138 
Right-of-use assets   30               30 
Total non-current assets   168    73,516    (65,891)      7,793 
TOTAL ASSETS   5,870    73,555    (61,646)      17,779 
                        
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ DEFICIT                       
Accounts payable   1,032    1,594    1,751  B   4,377 
Lease liabilities, current portion   33               33 
Accrued expenses and other current liabilities   1,150               1,150 
Total current liabilities   2,215    1,594    1,751      5,560 
Non-current liabilities:                       
Deferred underwriting fee       2,911           2,911 
Warrant liability       2,143    (2,143)  G    
Total non-current liabilities       5,054    (2,143)      2,911 
Total liabilities   2,215    6,648    (392)      8,471 

 

3

 

 

Revelation Biosciences, Inc. and Petra Acquisition Inc.
Unaudited Pro Forma Condensed Combined Balance Sheet — (Continued)
(In thousands), except per share amounts
As of September 30, 2021

 

   As of
September 30,
2021
   Transaction      As of
September 30,
2021
 
   Revelation
(Historical)
   Petra
(Historical)
   Accounting
Adjustments
      Pro Forma
Combined
 
COMMITMENTS AND CONTINGENCIES                   
Temporary equity:                   
Common stock subject to possible redemption       73,509    (73,509)  D    
                        
Stockholders’ equity (deficit):                       
Series A Preferred stock   3,904        (3,904)  F    
Series A-1 Preferred stock   3,578        (3,578)  F    
Common stock   2    2    7   F   12 
              1   D     
Additional paid-in capital   6,828        12,780   D   26,296 
              (6,604)  E     
              7,474   F     
              2,143   G     
              3,675   B     
Retained earnings (deficit)   (10,657)   (6,604)   6,604   E   (17,000)
              (6,343)  B     
Total stockholders’ equity (deficit)   3,655    (6,602)   12,255       9,308 
TOTAL LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)   5,870    73,555    (61,646)      17,779 

 

Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet

 

The pro forma adjustments included in the unaudited pro forma condensed combined balance sheet as of September 30, 2021, are as follows:

 

(A)Reflects the reclassification of marketable securities to cash based on actual redemptions.

 

(B)Represents preliminary estimated direct and incremental transaction costs to be incurred. These costs are accounted for a reduction in the combined cash account with a corresponding reduction in APIC consistent with the treatment described in SEC Staff Accounting Bulletin Topic 5.A.

 

(C)Reflects the reclassification of marketable securities to cash.

 

(D)Reflects the reclassification of common stock based on actual redemptions to permanent equity.

 

(E)Represents recapitalization of Petra’s historical accumulated deficit.

 

(F)Represents recapitalization of Revelation Biosciences, Inc. preferred stock.

 

(G)Represents the reclassification of the Petra pre-merger private warrant liability to equity due to the terms of the private warrants being identical to the public warrants upon the completion of the Merger.

 

4

 

 

Revelation Biosciences, Inc. and Petra Acquisition, Inc.
Unaudited Pro Forma Condensed Combined Statement of Operations
(In thousands, except per share amounts)
For the nine-months ended September 30, 2021

 

   For the
Nine-months
Ended
September 30,
2021
   Transaction      For the
Nine-months Ended September 30,
2021
 
   Revelation
(Historical)
   Petra
(Historical)
   Accounting
Adjustments
      Pro Forma
Combined
 
Revenue:                   
Revenue  $   $   $      $ 
Operating costs and expenses:                       
Research and development   4,249               4,249 
General and administrative   3,844    2,155           5,999 
Total operating costs and expenses   8,093    2,155           10,248 
Loss from operations   (8,093)   (2,155)          (10,248)
Other income (expense):                       
Other income (expense):   (33)              (33)
Interest income (expense)       6    (6)  AA    
Unrealized loss on marketable securities       (17)          (17)
Change in the fair value of warrants       1,256           1,256 
Total other income (expense)   (33)   1,245    (6)      1,206 
Net loss   (8,126)   (910)   (6)      (9,042)
Income tax provision                   
Net loss  $(8,126)  $(910)  $(6)     $(9,042)

 

    Historical Weighted-Average Shares Outstanding    Historical Weighted-Average Shares Outstanding  

Pro Forma

Weighted-Average Shares

Outstanding

 
Weighted common shares outstanding – basic   2,091,463    1,819,538    12,944,213 
Weighted common shares outstanding – diluted   2,091,463    1,819,538    12,944,213 
Basic net (loss) income per share  $(3.89)  $(0.50)  $(0.70)
Diluted net (loss) income per share  $(3.89)  $(0.50)  $(0.70)

 

5

 

 

Revelation Biosciences, Inc. and Petra Acquisition, Inc.
Unaudited Pro Forma Condensed Combined Statement of Operations
(In thousands, except per share amounts)
For the year-ended December 31, 2020

 

   For the
Year Ended
December 31,
2020
   Transaction      For the
Year Ended
December 31,
2020
 
   Revelation
(Historical)
   Petra
(Historical)
   Accounting
Adjustments
      Pro Forma
Combined
 
Revenue:                   
Revenue  $   $   $      $ 
Operating costs and expenses:                       
Research and development   1,707               1,707 
General and administrative   823    145           968 
Total operating costs and expenses   2,530    145           2,675 
Loss from operations   (2,530)   (145)          (2,675)
Other expense:                       
Interest income       9    (9)  AA    
Unrealized loss on marketable securities       (2)          (2)
Interest earned on cash held in Trust Account       2           2
Change in fair value of warrant liability       (1,494)          (1,494)
Total other expense       (1,485)   (9)      (1,494)
Net loss   (2,530)   (1,630)   (9)      (4,169)
Income tax provision                   
Net loss  $(2,530)  $(1,630)  $(9)     $(4,169)

 

   Historical Weighted-Average Shares Outstanding   Historical Weighted-Average Shares Outstanding  

Pro Forma

Weighted-Average Shares

Outstanding

 
Weighted common shares outstanding – basic   2,234,664    2,409,951    12,944,213 
Weighted common shares outstanding – diluted   2,234,664    2,409,951    12,944,213 
Basic net income (loss) per share  $(1.13)  $(0.68)  $(0.32)
Diluted net income (loss) per share  $(1.13)  $(0.68)  $(0.32)

 

Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations

 

The pro forma adjustments included in the unaudited pro forma condensed combined statement of operations for the nine-months ended September 30, 2021, and the year ended December 31, 2020, are as follows:

 

(AA) Represents the elimination of interest income earned on investments held in Trust Account

 

6

 

 

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

 

1.Basis of Presentation and Accounting Policies

 

The Merger will be accounted for as a reverse recapitalization in accordance with GAAP because Revelation has been determined to be the accounting acquirer under ASC 805. Under this method of accounting, Petra will be treated as the “acquired” company for financial reporting purposes. Accordingly, the consolidated assets, liabilities and results of operations of Revelation will become the historical financial statements of New Revelation, and Petra’s assets, liabilities and results of operations will be consolidated with Revelation beginning on the acquisition date. For accounting purposes, the financial statements of New Revelation will represent a continuation of the financial statements of Revelation with the Transaction being treated as the equivalent of Revelation issuing stock for the net assets of Petra, accompanied by a recapitalization. The net assets of Petra will be stated at historical costs, with no goodwill or other intangible assets recorded. Operations prior to the Merger will be presented as those of Revelation in future reports of New Revelation.

 

The unaudited pro forma condensed combined financial information reflects all Petra’s public shareholders that exercised redemption rights with respect to their public shares. A total of 6,024,819 shares were redeemed for an aggregate redemption value of approximately $61.2 million. The resulting redemptions will provide Revelation with cash at closing of the Business Combination of greater than the $5,000,001 Net Tangible Asset value Pursuant to the Business Combination Agreement.

 

2.Adjustments to Unaudited Pro Forma Condensed Combined Financial Information

 

The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. The adjustments in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an illustrative understanding of New Revelation upon consummation of the Merger in accordance with GAAP. Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial information are described in the accompanying notes.

 

The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Merger occurred on the dates indicated, and does not reflect adjustments for any anticipated synergies, operating efficiencies, tax savings or cost savings. Any cash proceeds remaining after the consummation of the Merger and the other related events contemplated by the Business Combination Agreement are expected to be used for general corporate purposes. The unaudited pro forma condensed combined financial information does not purport to project the future operating results or financial position of New Revelation following the completion of the Merger. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of these unaudited pro forma condensed combined financial information and are subject to change as additional information becomes available and analyses are performed. Petra and Revelation have not had any historical relationship prior to the transactions. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.

 

The following summarizes the pro forma shares of New Revelation Common Stock issued and outstanding immediately after the Merger, presented under the above scenarios:

 

   Shares   % 
Revelation Shareholders   9,871    76.3%
Petra Acquisition Inc. Shareholders   3,073    23.7%
Pro Forma Common Stock at September 30, 2021(1)   12,944    100.0%

 

 

(1)The table does not include 10.5 million of Public Warrants, 167,867 Rollover Warrants and 460,706 Rollover RSU’s.

 

7

 

 

If the actual facts are different than these assumptions, then the amounts and shares outstanding in the unaudited pro forma condensed combined financial information will be different and those changes could be material.

 

Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial statements are described in the accompanying notes. The unaudited pro forma condensed combined financial statements have been presented for illustrative purposes only and are not necessarily indicative of the operating results and financial position that would have been achieved had the Merger occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial statements do not purport to project the future operating results or financial position of New Revelation following the completion of the Merger. The unaudited pro forma adjustments represent New Revelation management’s estimates based on information available as of the dates of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed.

 

The pro forma basic and diluted income per share amounts presented in the unaudited pro forma condensed combined statements of operations are based upon the number of the Combined Company’s shares outstanding, assuming the Business Combination occurred on January 1, 2020.

 

3.Income (loss) per share

 

Represents the income per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January 1, 2020. As the Business Combination and related equity transactions are being reflected as if they had occurred at the beginning of the periods presented, the calculation of weighted average shares outstanding for basic and diluted net income per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entirety of all periods presented.

 

   For the
Year Ended
December 31,
2020
 
  

Pro-Forma

Weighted-Shares

Outstanding

 
Pro forma net loss  $(4,170,371)
Weighted average shares outstanding of common stock – basic   12,944,213 
Weighted average shares outstanding of common stock – diluted   12,944,213 
Net income per share attributable to common stockholders – basic  $(0.32)
Net income per share attributable to common stockholders – diluted  $(0.32)

  

   For the
Nine-Months
Ended
September 30,
2021
 
  

Pro-Forma

Weighted-Shares

Outstanding

 
Pro forma net loss  $(9,042,763)
Weighted average shares outstanding of common stock – basic   12,944,213 
Weighted average shares outstanding of common stock – diluted   12,944,213 
Net loss per share attributable to common stockholders – basic  $(0.70)
Net loss per share attributable to common stockholders – diluted  $(0.70)

 

 

8

 

 

EX-101.SCH 4 revb-20220110.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 revb-20220110_def.xml XBRL DEFINITION FILE EX-101.LAB 6 revb-20220110_lab.xml XBRL LABEL FILE Class of Stock [Axis] Units, each consisting of one share of common stock and one-half of one redeemable warrant Common stock, par value $0.001 per share Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 revb-20220110_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 10, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 10, 2022
Current Fiscal Year End Date --12-31
Entity File Number 001-39603
Entity Registrant Name REVELATION BIOSCIENCES, INC.
Entity Central Index Key 0001810560
Entity Tax Identification Number 84-3898466
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4660 La Jolla Village Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code 650
Local Phone Number 800-3717
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of common stock and one-half of one redeemable warrant  
Title of 12(b) Security Units, each consisting of one share of common stock and one-half of one redeemable warrant
Trading Symbol REVBU
Security Exchange Name NASDAQ
Common stock, par value $0.001 per share  
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol REVB
Security Exchange Name NASDAQ
Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share  
Title of 12(b) Security Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share
Trading Symbol REVBW
Security Exchange Name NASDAQ
XML 9 ea154019-8k_revelation_htm.xml IDEA: XBRL DOCUMENT 0001810560 2022-01-10 2022-01-10 0001810560 REVB:UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember 2022-01-10 2022-01-10 0001810560 REVB:CommonStockParValue0.001PerShareMember 2022-01-10 2022-01-10 0001810560 REVB:RedeemableWarrantsEachExercisableForShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2022-01-10 2022-01-10 iso4217:USD shares iso4217:USD shares 0001810560 false --12-31 8-K 2022-01-10 REVELATION BIOSCIENCES, INC. DE 001-39603 84-3898466 4660 La Jolla Village Drive Suite 100 San Diego CA 92122 650 800-3717 false false false false Units, each consisting of one share of common stock and one-half of one redeemable warrant REVBU NASDAQ Common stock, par value $0.001 per share REVB NASDAQ Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share REVBW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 4 118 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://petraacquisition.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea154019-8k_revelation.htm ea154019ex21-1_revelation.htm ea154019ex99-1_revelation.htm revb-20220110.xsd revb-20220110_def.xml revb-20220110_lab.xml revb-20220110_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea154019-8k_revelation.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "revb-20220110_def.xml" ] }, "inline": { "local": [ "ea154019-8k_revelation.htm" ] }, "labelLink": { "local": [ "revb-20220110_lab.xml" ] }, "presentationLink": { "local": [ "revb-20220110_pre.xml" ] }, "schema": { "local": [ "revb-20220110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 3, "memberStandard": 0, "nsprefix": "REVB", "nsuri": "http://petraacquisition.com/20220110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea154019-8k_revelation.htm", "contextRef": "From2022-01-10to2022-01-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://petraacquisition.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea154019-8k_revelation.htm", "contextRef": "From2022-01-10to2022-01-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "REVB_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://petraacquisition.com/20220110", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "domainItemType" }, "REVB_RedeemableWarrantsEachExercisableForShareOfCommonStockAtExercisePriceOf11.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share" } } }, "localname": "RedeemableWarrantsEachExercisableForShareOfCommonStockAtExercisePriceOf11.50PerShareMember", "nsuri": "http://petraacquisition.com/20220110", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "domainItemType" }, "REVB_UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units, each consisting of one share of common stock and one-half of one redeemable warrant" } } }, "localname": "UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember", "nsuri": "http://petraacquisition.com/20220110", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://petraacquisition.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001213900-22-002152-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-002152-xbrl.zip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end